- Conditions
- Unresectable Pleural Mesothelioma
- Interventions
- Volrustomig, Pemetrexed, Carboplatin, Cisplatin, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 863 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 14
- States / cities
- Santa Rosa, California • Aurora, Colorado • Jacksonville, Florida + 10 more
Clinical trials in Jacksonville, Florida
This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Jacksonville
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Spinal Duraplasty
- Interventions
- Adherus Dural Sealant System, DuraSeal Exact Dural Sealant System
- Device
- Lead sponsor
- Stryker Craniomaxillofacial
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 14
- States / cities
- Duarte, California • Sacramento, California • Stanford, California + 9 more
- Conditions
- Endometrial Cancer
- Interventions
- Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 57
- States / cities
- Little Rock, Arkansas • Duarte, California • La Jolla, California + 50 more
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 652
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more
- Conditions
- Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
- Interventions
- Ubamatamab, Marlotamig, Sarilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Irvine, California + 14 more
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Panitumumab, Sotorasib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 180
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 135 more
- Conditions
- SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis
- Interventions
- Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets
- Drug
- Lead sponsor
- Cogent Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more
- Conditions
- Wound Heal, Ulcer
- Interventions
- InnovaMatrix® AC
- Device
- Lead sponsor
- ConvaTec Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Fresno, California • Los Angeles, California • San Diego, California + 16 more
- Conditions
- Epilepsy, Epilepsy (Treatment Refractory)
- Interventions
- Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)
- Device
- Lead sponsor
- Epiminder America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 16 more
- Conditions
- Diabetic Retinopathy (DR)
- Interventions
- automatic analysis of fundus images performed by the software tool based on artificial intelligence
- Device
- Lead sponsor
- Centervue SpA
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Multiple Myeloma, Myeloma, Myeloma Multiple
- Interventions
- Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®), Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)
- Drug
- Lead sponsor
- K36 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 19
- States / cities
- San Francisco, California • Jacksonville, Florida • Miami, Florida + 15 more
- Conditions
- Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
- Interventions
- Prodigy Thrombectomy System, Symphony Thrombectomy System
- Device
- Lead sponsor
- Imperative Care, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 13
- States / cities
- Huntsville, Alabama • Clearwater, Florida • Jacksonville, Florida + 10 more